Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa multiple-dose study of BW-40202 in Chinese patients with IgA nephropathy
CTR20260337Phase 2Active
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BW-40202 in IgA nephropathy (IgAN), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
BW-40202
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20260337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260337.